Quick answer: There is no clear evidence of a GLP-1 diverticulitis link, meaning no proof that these drugs cause diverticulitis. It is not listed as a side effect in the Wegovy or Zepbound labels, a 2025 meta-analysis of 55 trials found GLP-1 drugs had little or no effect on most serious gastrointestinal events apart from gallstones and reflux, and a genetic study found no causal link with diverticulosis.[2][5] The bigger everyday issue is constipation, which affected 24% of adults on Wegovy 2.4 mg versus 11% on placebo.[6]
This guide explains what diverticular disease is, what the evidence says about GLP-1s and the colon, and how to manage constipation. For background on the drug class, see our GLP-1 basics hub, the semaglutide profile and the tirzepatide profile.
What are diverticulosis and diverticulitis?
Diverticula are small pouches that bulge out through weak spots in the wall of the colon. Having them without symptoms is called diverticulosis, which is very common with age. When they cause symptoms or complications it is called diverticular disease, and when a pouch becomes inflamed or infected it is diverticulitis.[1]
The 2026 Fiesole international consensus lists known risk factors: high dietary fiber is protective, while smoking, obesity and the use of NSAIDs (like ibuprofen), steroids and opioids raise risk.[1] About 20% to 25% of people with diverticulosis develop symptoms.[1]
Do GLP-1 drugs raise diverticulitis risk?
Here is what the evidence shows, from strongest to weakest:
- Randomized trials: A 2025 meta-analysis in Gastroenterology pooled 55 placebo-controlled trials with 106,395 people. GLP-1 drugs increased gallstones and probably reflux, but probably had little or no effect on other serious events it tracked, including intestinal obstruction, ileus, perforation, bleeding and gastrointestinal ischemia. Diverticulitis was not one of the outcomes analyzed.[2]
- Genetic study: A 2024 Mendelian randomization study, which uses genetic variation to estimate cause and effect, found no causal evidence that GLP-1 drug targets affect diverticulosis or other GI diseases studied.[5]
- Labels: Neither the Wegovy nor the Zepbound label lists diverticulitis. Both list constipation as common, and Wegovy’s label includes postmarketing reports of ileus, intestinal obstruction and severe constipation including fecal impaction.[6][7]
- Health-record study: A 2023 study of people using GLP-1 drugs for weight loss found a higher risk of bowel obstruction than with bupropion-naltrexone (hazard ratio 4.22), though the number of events was small and the confidence interval was wide.[3]
- Case reports: A 2025 report described a 53-year-old man with known, previously silent diverticular disease who developed complicated diverticulitis with a stricture and liver abscesses after losing 25 kg on tirzepatide. The authors proposed slower colon movement as a possible factor, but a single case cannot show cause.[4]
Why constipation matters
GLP-1 drugs slow movement through the digestive tract, and people eat much less, often with less fiber and fluid. Constipation is one of the most common side effects:
| Drug | Constipation on drug | Placebo |
|---|---|---|
| Wegovy 2.4 mg | 24% | 11% |
| Wegovy 7.2 mg | 20% | 8% |
| Zepbound 5 / 10 / 15 mg | 17% / 14% / 11% | 5% |
Sources: Wegovy and Zepbound labels.[6][7]
Hard stools and straining raise pressure in the colon. Whether that translates into more diverticulitis on GLP-1 drugs has not been shown, but preventing constipation is sensible for everyone, and especially for people with diverticular disease.
How to manage constipation on a GLP-1
- Drink enough fluids, spread through the day.
- Increase fiber gradually, from foods such as oats, beans, lentils, fruit and vegetables. The Fiesole consensus notes that high fiber intake is protective against diverticular disease.[1]
- Stay active. Regular walking helps bowel movement.
- Consider an over-the-counter laxative with your clinician’s input. The 2023 AGA-ACG guideline on chronic constipation made strong recommendations for polyethylene glycol (an osmotic laxative) and conditional recommendations for fiber supplements, magnesium oxide and senna.[8] That guideline was written for chronic constipation generally, not GLP-1 users specifically.
- Avoid opioid pain relievers where possible, which worsen constipation and are linked to a higher risk of diverticular disease.[1]
- Talk about the dose. If constipation is severe, your prescriber may slow dose increases.
If you have a history of diverticulitis
Diverticular disease is not listed as a reason to avoid GLP-1 drugs.[6][7] Practical steps to discuss with your prescriber:
- Share details of past flares, especially complicated ones (abscess, stricture, perforation, surgery).
- Start a constipation plan before your first dose.
- Agree on what to do with your GLP-1 dose if you have a flare and are on a liquid diet or vomiting.
- Know the warning signs below.
How diverticulitis is usually treated
Treatment depends on severity. The Fiesole consensus says routine antibiotics are not recommended for acute uncomplicated diverticulitis, and that elective surgery should be individualized based on quality of life rather than the number of episodes.[1] Complicated cases, such as those with an abscess or perforation, need hospital care. Tell every clinician involved that you take a GLP-1 drug.
Related guides
Many digestive symptoms overlap. See our guides to GLP-1 nausea, GLP-1s and the gallbladder and stopping GLP-1s before surgery, which matters if you need a colonoscopy.
This article is general information. Your clinician can weigh your bowel history against the benefits of treatment.
